NCT01730417View on ClinicalTrials.gov

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

June 30, 2011

Study Completion Date

July 31, 2011

Conditions
Neuroendocrine TumorsHeart Failure
Interventions
DRUG

no carrier added metaiodobenzylguanidine

Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Molecular Insights Pharmaceuticals

UNKNOWN

lead

Bennett Chin

OTHER

NCT01730417 - Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG | Biotech Hunter | Biotech Hunter